RGENTA THERAPEUTICS
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
RGENTA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rgentatx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
56.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Similar Organizations
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Seed Round - Rgenta Therapeutics
Kaitai Capital
Kaitai Capital investment in Seed Round - Rgenta Therapeutics
Vivo Capital
Vivo Capital investment in Seed Round - Rgenta Therapeutics
Matrix Partners China
Matrix Partners China investment in Seed Round - Rgenta Therapeutics
Legend Star
Legend Star investment in Seed Round - Rgenta Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - Rgenta Therapeutics
Kaitai Capital
Kaitai Capital investment in Seed Round - Rgenta Therapeutics
Official Site Inspections
http://www.rgentatx.com Semrush global rank: 4.33 M Semrush visits lastest month: 2.64 K
- Host name: staticip2.multiscreensite.com
- IP address: 100.24.208.97
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Rgenta Therapeutics"
About Us | RNA-Targeting | Rgenta Therapeutics
Rgenta develops RNA-targeting therapies to address drug discovery challenges. Contact us to learn more about our innovative approach.See details»
Our Science | RNA-Targeting | Rgenta Therapeutics
Rgenta develops RNA-targeting medicines to modulate disease proteins. Learn about our innovative approaches in drug development.See details»
Rgenta Therapeutics - Crunchbase Company Profile
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.See details»
Rgenta Therapeutics 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Rgenta Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Rgenta Therapeutics | Leukemia and Lymphoma Society
Jan 30, 2024 For more information about Rgenta, visit rgentatx.com. Recent News December 4, 2024 - announced that it has entered into a multi-year, multi-target strategic research alliance with …See details»
Rgenta Therapeutics Inc. | LinkedIn
Rgenta Therapeutics Inc. | 6,032 followers on LinkedIn. We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecules. | Rgenta Therapeutics is developing a …See details»
Rgenta | Venture Fund | Boehringer Ingelheim
Rgenta Therapeutics is a clinical stage biotechnology company developing a pipeline of oral RNA-targeting small molecule medicines with an initial focus on oncology and neurology disorders. Our …See details»
Rgenta Therapeutics: Employee Directory | ZoomInfo.com
May 25, 2024 Rgenta Therapeutics Employee Directory Rgenta Therapeutics corporate office is located in 300 Tradecenter Ste 6600, Woburn, Massachusetts, 01801, United States and has 36 …See details»
Rgenta Therapeutics, Inc. - Drug pipelines, Patents, …
May 7, 2025 Explore Rgenta Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 18 news, and 2 literature, Disease Domain:Neoplasms ...See details»
Rgenta Therapeutics - Profiles & Contacts - Crunchbase
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.See details»
Rgenta Therapeutics - Executive Bio, Top Executies, and Transitions ...
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify …See details»
Rgenta Therapeutics Inc. Information - RocketReach
Rgenta Therapeutics Inc. is a Biotechnology Research, Business Services General, and Drug Discovery company located in Woburn, Massachusetts with 30 employees. Find top employees, …See details»
Rgenta Therapeutics Raises $52M in Series A Financing
Nov 29, 2022 /PRNewswire/ -- Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with...See details»
Rgenta Therapeutics Inc. Company Overview, Contact Details ...
May 8, 2023 Learn more about Rgenta Therapeutics Inc.'s company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Rgenta CEO and Key Executive Team - Craft.co
Rgenta's Co-Founder and CEO is Simon Xi. Other executives include Travis T. Wager, Co-Founder, President and CSO; Jae Lee, VP of Translational Pharmacology and 11 others. See the full …See details»
Rgenta Company Profile - Office Locations, Competitors, Revenue
Rgenta has 5 employees at their 1 location. See insights on Rgenta including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Rgenta Therapeutics, Inc. Company Profile: Financials, Valuation, and ...
Rgenta Therapeutics, Inc. is a privately-held company that develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. …See details»
Rgenta: Revenue, Worth, Valuation & Competitors 2025
Rgenta has an estimated revenue of $7.8M, and 31 employees. Alternatives of Rgenta are Imaging Endpoints, Southern Scripts and Alfasigma USA.See details»
Rgenta - 2025 Company Profile & Team - Tracxn
Jun 13, 2025 Rgenta - Developer of RNA-based therapeutics for multiple disorders. Raised a total funding of $90M over 4 rounds from 12 investors.See details»
Company Details :: Pink Sheet
Want to become a subscriber?Subscribers get more company details, updates, company financials and company products.See details»